{
    "clinical_study": {
        "@rank": "168196", 
        "arm_group": [
            {
                "arm_group_label": "OAV Alone", 
                "arm_group_type": "Experimental", 
                "description": "Participants will continue their prebaseline OAV treatment alone from baseline to Week 48."
            }, 
            {
                "arm_group_label": "OAV + GS-4774 2 YU", 
                "arm_group_type": "Experimental", 
                "description": "Participants will continue their prebaseline OAV from baseline to Week 48, and will receive GS-4774 2 yeast units (YU) from baseline to Week 20."
            }, 
            {
                "arm_group_label": "OAV + GS-4774 10 YU", 
                "arm_group_type": "Experimental", 
                "description": "Participants will continue their prebaseline OAV from baseline to Week 48, and will receive GS-4774 10 YU from baseline to Week 20."
            }, 
            {
                "arm_group_label": "OAV + GS-4774 40 YU", 
                "arm_group_type": "Experimental", 
                "description": "Participants will continue their prebaseline OAV from baseline to Week 48, and will receive GS-4774 40 YU from baseline to Week 20."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized, open-label, multicenter Phase 2 study to evaluate the safety and\n      efficacy of GS-4774 in subjects with chronic hepatitis B (CHB) viral infection who have been\n      virally suppressed with an oral antiviral medication.  One hundred and seventy-five subjects\n      will be randomized in a 1:2:2:2 ratio to the treatment arms for 20 weeks."
        }, 
        "brief_title": "Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic HBV Infection", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B", 
                "Hepatitis, Chronic", 
                "Hepatitis B, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Ability to understand and sign a written informed consent form, which must be\n             obtained prior to initiation of study procedures\n\n          -  Currently taking an HBV oral antiviral medication\n\n          -  Documented evidence of chronic HBV infection (eg, HBsAg positive for more than 6\n             months)\n\n          -  Virally-suppressed (HBV DNA below the lower limit of quantification [LLOQ] by for \u2265 1\n             year)\n\n        Exclusion Criteria:\n\n          -  Cirrhosis\n\n          -  Inadequate liver function\n\n          -  Co-infection with hepatitic C virus (HCV), HIV or hepatitic D virus (HDV)\n\n          -  Evidence of hepatocellular carcinoma\n\n          -  Significant cardiovascular, pulmonary, or neurological disease\n\n          -  Females who are pregnant or may wish to become pregnant during the study\n\n          -  Received solid organ or bone marrow transplant\n\n          -  Use of another investigational agents within 3 months of screening\n\n          -  Current alcohol or substance abuse judged by the investigator to potentially\n             interfere with compliance\n\n          -  History of demyelinating disease (Guillain-Barre), Bell's Palsy, Crohn's disease\n             ulcerative colitis, autoimmune disease\n\n          -  Known hypersensitivity to study drug, metabolites or formulation excipients\n\n          -  Malignancy within 5 years prior to screening, with the exception of specific cancers\n             that are cured by surgical resection (basal cell skin cancer, etc). Participants\n             under evaluation for possible malignancy are not eligible."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "175", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01943799", 
            "org_study_id": "GS-US-330-0101"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "OAV + GS-4774 2 YU", 
                    "OAV + GS-4774 10 YU", 
                    "OAV + GS-4774 40 YU"
                ], 
                "description": "GS-4774 2, 10, or 40 YU administered as a subcutaneous injection every 4 weeks for a total of 6 doses", 
                "intervention_name": "GS-4774", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "OAV Alone", 
                    "OAV + GS-4774 2 YU", 
                    "OAV + GS-4774 10 YU", 
                    "OAV + GS-4774 40 YU"
                ], 
                "description": "Oral antiviral (OAV) regimen as administered prior to study enrollment (tenofovir disoproxil fumarate, entecavir, adefovir, lamivudine, or telbivudine either as single agents or in combination)", 
                "intervention_name": "OAV Regimen", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Hepatitis B (HBV)", 
            "Oral antiviral (OAV)", 
            "GS-4774"
        ], 
        "lastchanged_date": "April 7, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90095"
                    }, 
                    "name": "Dumont-UCLA Liver Transplant Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pasadena", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91105"
                    }, 
                    "name": "Huntington Medical Research Institutes"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sacramento", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95825"
                    }, 
                    "name": "Kaiser Permanente"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92154"
                    }, 
                    "name": "Kaiser Permanente"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94118"
                    }, 
                    "name": "Kaiser Permanente"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Jose", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95128"
                    }, 
                    "name": "Silicon Valley Research Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33136"
                    }, 
                    "name": "University of Miami"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Northwestern Memorial Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21229"
                    }, 
                    "name": "Digestive Disease Associates, PA"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02111"
                    }, 
                    "name": "Tufts Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ann Arbor", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48109"
                    }, 
                    "name": "University of Michigan"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48202"
                    }, 
                    "name": "Henry Ford Hospital and Health System"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63104"
                    }, 
                    "name": "St.Louis University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Flushing", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11355"
                    }, 
                    "name": "Medical Pro-care"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Manhasset", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11030"
                    }, 
                    "name": "North Shore LIJ Health System"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Newport News", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23602"
                    }, 
                    "name": "Bon Secours St. Mary's Hospital of Richmond"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Grafton", 
                        "country": "New Zealand", 
                        "zip": "1141"
                    }, 
                    "name": "Auckland Clinical Studies"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "New Zealand"
            ]
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B", 
        "overall_official": {
            "affiliation": "Gilead Sciences", 
            "last_name": "Anuj Gaggar, MD, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Mean change in log10 IU/mL serum hepatitis B surface antigen (HBsAg) from Baseline to Week 24", 
            "safety_issue": "No", 
            "time_frame": "Baseline to Week 24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01943799"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Mean change in log10 IU/mL serum HBsAg from Baseline to Weeks 12 and 48", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Weeks 12 and 48"
            }, 
            {
                "measure": "Proportion of participants with HBsAg loss and HBsAg seroconversion at Weeks 24 and 48", 
                "safety_issue": "No", 
                "time_frame": "Weeks 24 and 48"
            }, 
            {
                "measure": "Proportion of participants with hepatitis B e antigen (HBeAg) loss and HBeAg seroconversion at Weeks 24 and 48", 
                "safety_issue": "No", 
                "time_frame": "Weeks 24 and 48"
            }, 
            {
                "measure": "Proportion of participants with a 1-log decline in HBsAg at Weeks 12, 24, and 48", 
                "safety_issue": "No", 
                "time_frame": "Weeks 12, 24, and 48"
            }
        ], 
        "source": "Gilead Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}